New HIV drug MK-4646 enters early human testing
NCT ID NCT07042945
First seen Jan 25, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early-stage study tests a new experimental drug, MK-4646, in 28 people with HIV-1 who have never taken HIV medication. The main goals are to see if the drug is safe and tolerable, and to measure how much it lowers the amount of virus in the blood. Participants will take the drug alone for a short time before starting standard HIV therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ARENSIA Exploratory Medicine ( Site 0001)
RECRUITINGBucharest, Bucharest, 021105, Romania
Contact Phone: •••-•••-••••
-
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 0002)
RECRUITINGChisinau, 2025, Moldova
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.